Roles for growth factors in cancer progression.
暂无分享,去创建一个
[1] S. Rafii,et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche , 2005, Nature.
[2] M. Shibuya,et al. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. , 1994, The Journal of biological chemistry.
[3] D. Hicklin,et al. Therapy-Induced Acute Recruitment of Circulating Endothelial Progenitor Cells to Tumors , 2006, Science.
[4] C. Heldin,et al. Non-Smad TGF-β signals , 2005, Journal of Cell Science.
[5] Roger R. Gomis,et al. TGFβ Primes Breast Tumors for Lung Metastasis Seeding through Angiopoietin-like 4 , 2008, Cell.
[6] C. Conover,et al. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. , 2006, Cancer research.
[7] R H Hruban,et al. Gene expression profiles in normal and cancer cells. , 1997, Science.
[8] A. Ullrich,et al. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant , 1994, Nature.
[9] S. Rafii,et al. Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth , 2001, Nature Medicine.
[10] Paul Stroobant,et al. Platelet-derived growth factor is structurally related to the putative transforming protein p28sis of simian sarcoma virus , 1983, Nature.
[11] W. Stetler-Stevenson,et al. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. , 1999, The Journal of clinical investigation.
[12] U. Krengel,et al. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. , 2009, Cancer research.
[13] H. Lane,et al. ERBB receptors and cancer: the complexity of targeted inhibitors , 2005, Nature Reviews Cancer.
[14] L. Mazzucchelli,et al. Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer , 2009, PloS one.
[15] John Kuriyan,et al. An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor , 2006, Cell.
[16] G. Sozzi,et al. Transforming activity of the chimeric sequence formed by the fusion of collagen gene COL1A1 and the platelet derived growth factor b-chain gene in dermatofibrosarcoma protuberans , 1998, Oncogene.
[17] B. Dutrillaux,et al. The insulin‐like growth factor I receptor gene is the target for the 15q26 amplicon in breast cancer , 1994, Genes, chromosomes & cancer.
[18] P. Leder,et al. NDF/heregulin induces persistence of terminal end buds and adenocarcinomas in the mammary glands of transgenic mice. , 1996, Oncogene.
[19] Y. Yarden,et al. Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.
[20] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[21] W. Birchmeier,et al. Hakai, a c-Cbl-like protein, ubiquitinates and induces endocytosis of the E-cadherin complex , 2002, Nature Cell Biology.
[22] Douglas B. Evans,et al. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. , 2008, Cancer research.
[23] Brian Bierie,et al. Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment. , 2008, Cancer research.
[24] Meir J. Stampfer,et al. Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study , 1998 .
[25] Ryuji Kobayashi,et al. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. , 2005, Cancer research.
[26] Z. Hua. Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer , 2006 .
[27] C. Niehrs,et al. Silencing of TGF-beta signalling by the pseudoreceptor BAMBI. , 1999, Nature.
[28] C R King,et al. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. , 1987, Science.
[29] S. Karpatkin,et al. Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype. , 2006, Cancer cell.
[30] N. Hanna. Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy , 2008 .
[31] C. Niehrs,et al. Silencing of TGF-β signalling by the pseudoreceptor BAMBI , 1999, Nature.
[32] D. Hanahan,et al. Deregulation of both imprinted and expressed alleles of the insulin–like growth factor 2 gene during β–cell tumorigenesis , 1995, Nature Genetics.
[33] M. Sliwkowski,et al. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. , 2003, Molecular cell.
[34] Erik Sahai,et al. Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop. , 2005, Cancer research.
[35] Dennis C. Sgroi,et al. Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion , 2005, Cell.
[36] Forest M White,et al. Oncogenic EGFR Signaling Networks in Glioma , 2009, Science Signaling.
[37] M. Sporn,et al. Autocrine secretion and malignant transformation of cells. , 1980, The New England journal of medicine.
[38] H. Wiley,et al. The Enhanced Tumorigenic Activity of a Mutant Epidermal Growth Factor Receptor Common in Human Cancers Is Mediated by Threshold Levels of Constitutive Tyrosine Phosphorylation and Unattenuated Signaling* , 1997, The Journal of Biological Chemistry.
[39] A. Citri,et al. EGF–ERBB signalling: towards the systems level , 2006, Nature Reviews Molecular Cell Biology.
[40] K. Makino,et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor , 2001, Nature Cell Biology.
[41] Christopher U. Jones,et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. , 2006, The New England journal of medicine.
[42] T. Sjöblom,et al. The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. , 1999, Cancer research.
[43] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[44] Apurva A Desai,et al. Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.
[45] A. Ullrich,et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences , 1984, Nature.
[46] J. Epstein. Precursor lesions to prostatic adenocarcinoma , 2008, Virchows Archiv.
[47] I. Amit,et al. A reciprocal tensin-3–cten switch mediates EGF-driven mammary cell migration , 2007, Nature Cell Biology.
[48] G. Colditz,et al. Common genetic variation in IGF1, IGFBP-1, and IGFBP-3 in relation to mammographic density: a cross-sectional study , 2007, Breast Cancer Research.
[49] J. Pichler,et al. Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies. , 2007, Oligonucleotides.
[50] C. Heldin,et al. Non-Smad TGF-beta signals. , 2005, Journal of cell science.
[51] L. Cantley,et al. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[52] Alejandra Bruna,et al. High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. , 2007, Cancer cell.
[53] Ross Tubo,et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis , 2007, Nature.
[54] Takayuki Asahara,et al. Isolation of Putative Progenitor Endothelial Cells for Angiogenesis , 1997, Science.
[55] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[56] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[57] Keith R. Johnson,et al. N-Cadherin Promotes Motility in Human Breast Cancer Cells Regardless of Their E-Cadherin Expression , 1999, The Journal of cell biology.
[58] Samy Lamouille,et al. Cell size and invasion in TGF-β–induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway , 2007, The Journal of cell biology.
[59] T. Stukel,et al. Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer. , 1992, Cancer Research.
[60] L. Presta,et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.
[61] D. Hicklin,et al. Effect of p53 Status on Tumor Response to Antiangiogenic Therapy , 2002, Science.
[62] J. Folkman. Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.
[63] M. Stratton,et al. The cancer genome , 2009, Nature.
[64] A. Ostman,et al. Cancer-associated fibroblasts and tumor growth--bystanders turning into key players. , 2009, Current opinion in genetics & development.
[65] Jonas Larsson,et al. Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling. , 2003, Molecular cell.
[66] Y. Yarden,et al. Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis , 2009, Proceedings of the National Academy of Sciences.
[67] Y. Yarden,et al. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[68] R. Henrique,et al. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. , 2006, Neoplasia.
[69] R. Kobayashi,et al. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells (Cancer Research (2005) 65, (11118-11128)) , 2008 .
[70] R. Lupu,et al. Heregulin is sufficient for the promotion of tumorigenicity and metastasis of breast cancer cells in vivo. , 2003, Molecular cancer research : MCR.
[71] J. Minna,et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. , 2005, Cancer research.
[72] K. Kinzler,et al. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[73] A. Ullrich,et al. Growth factor receptor tyrosine kinases. , 1988, Annual review of biochemistry.
[74] G. Todaro,et al. Transformation by murine and feline sarcoma viruses specifically blocks binding of epidermal growth factor to cells , 1976, Nature.
[75] Z. Werb. ECM and Cell Surface Proteolysis: Regulating Cellular Ecology , 1997, Cell.
[76] M. Bissell,et al. Modulation of secreted proteins of mouse mammary epithelial cells by the collagenous substrata , 1984, The Journal of cell biology.
[77] Napoleone Ferrara,et al. Vascular Endothelial Growth Factor Signaling Pathways: Therapeutic Perspective , 2006, Clinical Cancer Research.
[78] S. Rafii,et al. The vascular endothelial growth factor receptor (VEGFR‐1) supports growth and survival of human breast carcinoma , 2006, International journal of cancer.
[79] H. Werner,et al. Targeting the IGF1 axis in cancer proliferation , 2009, Expert opinion on therapeutic targets.
[80] V. Hamburger,et al. A NERVE GROWTH-STIMULATING FACTOR ISOLATED FROM SARCOM AS 37 AND 180. , 1954, Proceedings of the National Academy of Sciences of the United States of America.
[81] J. Pichler,et al. Inhibition of TGF-β2 with AP 12009 in Recurrent Malignant Gliomas: From Preclinical to Phase I/II Studies , 2007 .
[82] M. Giacca,et al. Anti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels , 2007, Cell.
[83] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[84] Bing Li,et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.
[85] Robert A. Weinberg,et al. TGF-β-induced apoptosis is mediated by the adapter protein Daxx that facilitates JNK activation , 2001, Nature Cell Biology.
[86] Yosef Yarden,et al. Cancer therapeutic antibodies come of age: Targeting minimal residual disease , 2007, Molecular oncology.
[87] J. Brugge,et al. ErbB2 and TGF-beta: A Cooperative Role in Mammory Tumor Progression? , 2004, Cell cycle.
[88] M. Sela,et al. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. , 1988, Journal of the National Cancer Institute.
[89] A. Adjei,et al. Phase I Dose Escalation Study of the Anti–Insulin-Like Growth Factor-I Receptor Monoclonal Antibody CP-751,871 in Patients with Refractory Solid Tumors , 2007, Clinical Cancer Research.
[90] A. Musolino,et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[91] J. Baselga,et al. Targeting Tyrosine Kinases in Cancer: The Second Wave , 2006, Science.
[92] M. V. Dinther,et al. The Tumor Suppressor Smad 4 Is Required for Transforming Growth Factor B – Induced Epithelial to Mesenchymal Transition and Bone Metastasis of Breast Cancer Cells , 2006 .
[93] S. Talbot,et al. Viruses and tumours--an update. , 2004, European journal of cancer.
[94] John Kuriyan,et al. Mechanism for Activation of the EGF Receptor Catalytic Domain by the Juxtamembrane Segment , 2009, Cell.
[95] Gerhard Christofori,et al. EMT, the cytoskeleton, and cancer cell invasion , 2009, Cancer and Metastasis Reviews.
[96] F. Pépin,et al. Stromal gene expression predicts clinical outcome in breast cancer , 2008, Nature Medicine.
[97] Jimmy Lin,et al. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4 , 2009, Nature Genetics.
[98] A. Halpern,et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. , 2005, The oncologist.
[99] Mindy I. Davis,et al. A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.
[100] B. Vogelstein,et al. A genetic model for colorectal tumorigenesis , 1990, Cell.
[101] D. Coppola,et al. Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts , 1994, Molecular and cellular biology.
[102] Martin A. Nowak,et al. Genetic Progression and the Waiting Time to Cancer , 2007, PLoS Comput. Biol..
[103] R. Akhurst,et al. TGF beta inhibition for cancer therapy. , 2006, Current cancer drug targets.
[104] P. Seeburg,et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells , 1984, Nature.
[105] M. J. van de Vijver,et al. Immunohistochemical categorisation of ductal carcinoma in situ of the breast , 2007, British Journal of Cancer.
[106] A. Goddard,et al. Chromosome aberrations and cancer. , 1991, Science.
[107] Mahlon D. Johnson,et al. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. , 1993, The Journal of clinical investigation.
[108] A. Chatterjee,et al. Mitochondrial DNA mutations in human cancer , 2006, Oncogene.
[109] T. Hubbard,et al. A census of human cancer genes , 2004, Nature Reviews Cancer.
[110] R. McLendon,et al. Robust Detection of EGFR Copy Number Changes and EGFR Variant III: Technical Aspects and Relevance for Glioma Diagnostics , 2009, Brain pathology.
[111] Hyun-soo Cho,et al. Structure of the Extracellular Region of HER3 Reveals an Interdomain Tether , 2002, Science.
[112] T. Golde,et al. γ-Secretase Cleavage and Nuclear Localization of ErbB-4 Receptor Tyrosine Kinase , 2001, Science.
[113] Hua Guo,et al. 14-3-3zeta overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival. , 2009, Cancer research.
[114] Yosef Yarden,et al. The Achilles Heel of ErbB-2/HER2: Regulation by the Hsp90 Chaperone Machine and Potential for Pharmacological Intervention , 2004, Cell cycle.
[115] M. Sporn,et al. Isolation from murine sarcoma cells of novel transforming growth factors potentiated by EGF , 1982, Nature.